Protagenic Therapeutics Appoints New Directors and CMO
Ticker: PTIXW · Form: 8-K · Filed: Nov 5, 2025 · CIK: 1022899
| Field | Detail |
|---|---|
| Company | Protagenic Therapeutics, Inc.\New (PTIXW) |
| Form Type | 8-K |
| Filed Date | Nov 5, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointment
Related Tickers: PTIX
TL;DR
Protagenic adds Epstein & Johnson to board, Epstein also named CMO, effective Nov 3.
AI Summary
Protagenic Therapeutics, Inc. announced on November 3, 2025, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. David M. Epstein and Mr. David M. S. Johnson, and appointed Dr. Epstein as the new Chief Medical Officer. These changes are effective immediately.
Why It Matters
The appointment of new leadership and a Chief Medical Officer suggests a strategic shift or expansion in Protagenic's operational and medical development focus.
Risk Assessment
Risk Level: medium — Changes in executive and board leadership can indicate strategic shifts or internal challenges, requiring closer monitoring of the company's direction.
Key Players & Entities
- Protagenic Therapeutics, Inc. (company) — The reporting company
- Dr. David M. Epstein (person) — Elected as a new director and appointed as Chief Medical Officer
- Mr. David M. S. Johnson (person) — Elected as a new director
- November 3, 2025 (date) — Effective date of the reported changes
FAQ
Who were the new directors appointed to the board of Protagenic Therapeutics?
Dr. David M. Epstein and Mr. David M. S. Johnson were elected as new directors.
What new executive role was filled by Dr. David M. Epstein?
Dr. David M. Epstein was appointed as the Chief Medical Officer.
When were these changes effective?
The changes were effective as of November 3, 2025.
What was Protagenic Therapeutics' former company name?
Protagenic Therapeutics, Inc. was formerly known as Atrinsic, Inc. and NEW MOTION, INC., and MPLC, Inc. prior to those name changes.
What is Protagenic Therapeutics' Standard Industrial Classification code?
Protagenic Therapeutics, Inc.'s Standard Industrial Classification code is 2834, for Pharmaceutical Preparations.
Filing Stats: 399 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2025-11-05 16:21:29
Filing Documents
- form8-k.htm (8-K) — 40KB
- 0001493152-25-020881.txt ( ) — 244KB
- ptix-20251103.xsd (EX-101.SCH) — 4KB
- ptix-20251103_def.xml (EX-101.DEF) — 26KB
- ptix-20251103_lab.xml (EX-101.LAB) — 36KB
- ptix-20251103_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROTAGENIC THERAPEUTICS, INC. Date: November 5, 2025 By: /s/ Alexander K. Arrow Name: Alexander K. Arrow Title: Chief Financial Officer